How semaglutide works: the GLP-1 science, explained
One gut hormone, one engineered molecule. The mechanism behind semaglutide's results — appetite, gastric emptying, glucose control — and why it doses once a week.
The incretin system, briefly
After you eat, your gut releases hormones called incretins that tell the pancreas to release insulin. The most important is glucagon-like peptide-1 (GLP-1), which does three things: slows stomach emptying so you feel full longer, acts on appetite centers in the brain to reduce hunger, and boosts glucose-dependent insulin secretion. Natural GLP-1 is broken down within minutes; semaglutide is engineered to resist that breakdown and act for days.
What semaglutide does at the receptor
Semaglutide binds and activates the GLP-1 receptor, amplifying all three effects of the natural hormone. The appetite and gastric-emptying effects are what patients notice most: meals feel satisfying sooner, hunger and food-seeking fall, and total caloric intake drops. Over months, this produces the weight loss quantified in STEP 1 (~14.9%) and sustained in STEP 5 (~15.2% at two years).
From receptor activity to real-world results
The receptor activity translates into four effects: appetite falls, meals feel satisfying sooner, blood-sugar swings flatten, and body weight and cardiometabolic markers improve. Real-world data mirror the trials — a US retrospective cohort found ~14.5% weight loss at 52 weeks with improvements in blood pressure, HbA1c, and lipids. The same delayed gastric emptying that drives fullness is also why nausea appears during escalation — mechanism and side effect are two faces of one action, unpacked in the side-effects guide.
Why it's a once-weekly injection
Natural GLP-1 lasts minutes. Semaglutide is engineered with a fatty-acid chain that binds albumin in the blood, extending its half-life to about a week — long enough for stable once-weekly dosing. That design underpins the slow titration schedule, which governs both efficacy and tolerability, and — on dose-tiered plans — your monthly bill. For the money side of the dose ladder, see our price-trends page.
Why the same mechanism helps blood sugar and weight
One elegant feature of GLP-1 biology is that a single mechanism addresses two problems at once, which is why semaglutide exists in both a diabetes form (Ozempic) and a weight-management form (Wegovy) at different doses. The glucose-dependent nature of its insulin effect is the crucial detail: semaglutide enhances insulin release only when blood sugar is elevated, and it simultaneously suppresses glucagon, the hormone that raises blood sugar. Because the insulin effect switches off as glucose normalizes, semaglutide alone carries a low risk of hypoglycemia — unlike older diabetes drugs that push insulin regardless of need.
The weight effect and the glucose effect share the same receptor activity but express through different tissues. In the pancreas, receptor activation modulates insulin and glucagon. In the gut, it slows emptying. In the brain — particularly the hypothalamus and hindbrain — it dampens the drive to eat. This distributed action is why semaglutide's benefits extend beyond the scale to blood pressure, lipids, and inflammatory markers, and ultimately to the cardiovascular event reduction seen in the SELECT trial. Understanding the mechanism also demystifies the practical rules: the once-weekly schedule follows from the engineered week-long half-life, the slow titration follows from the gut effects driving nausea, and the weight regain after stopping follows from the simple fact that the appetite signal disappears when the drug clears. Nothing about semaglutide's behavior is arbitrary once you see the biology underneath it — a useful frame when you're evaluating claims from any provider.
Frequently asked questions
How does semaglutide work?
Semaglutide is a GLP-1 receptor agonist that mimics the gut hormone GLP-1. It slows gastric emptying, reduces appetite via brain signaling, and enhances glucose-dependent insulin release. Together these reduce food intake and produce weight loss.
Why does semaglutide reduce appetite?
By activating GLP-1 receptors in appetite-regulating regions of the brain and slowing stomach emptying, semaglutide makes meals feel satisfying sooner and reduces hunger, lowering total caloric intake.
Is semaglutide the same as Ozempic and Wegovy?
Semaglutide is the active ingredient in both Ozempic (approved for type 2 diabetes) and Wegovy (approved for weight management). Compounded semaglutide contains the same molecule but is not FDA-approved and is a different regulatory category.
Why is semaglutide injected only once a week?
It's engineered with a fatty-acid chain that binds albumin in the blood, extending its half-life to about a week. That allows stable once-weekly dosing and a grace window for missed doses.
References
- Wilding JPH, et al. STEP 1. N Engl J Med. 2021.
- Novo Nordisk. Wegovy Prescribing Information — clinical pharmacology.
- Real-world SCOPE cohort: semaglutide 2.4 mg 52- and 68-week outcomes. Postgrad Med. 2025.
- Semaglutide Price Guide science journal, July 2026.
Clinical figures from published trials and FDA labeling; pricing from provider-advertised rates checked July 2026 and subject to change. Educational, not medical or financial advice.